Drug Trial Radar · NCT07663318
A Phase 1 Study to Evaluate the Relative Bioavailability of Octreotide Acetate Tablets(T25) Compared to MYCAPSSA® and The Food Effect on Pharmacokinetics Of Octreotide Acetate Tablets(T25)
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
18
Actual
Start
Jun 25, 2026
Primary completion
Jul 22, 2026
Study completion Jul 24, 2026
Sponsor
- Lead sponsor
- Triastek (Shanghai) LimitedIndustry
- Sponsor type
- Industry
- Collaborators
- Zibo Central Hospital
- First posted
- Jun 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The goal of this clinical trial\] is to to Assess the Food Effect on the Relative Bioavailability of Orally Administrated T25 in healthy volunteers. The main questions it aims to answer are: 1. How much of relative bioavailability of Orally Administrated T25 compared to Mycapssa? 2. What effects does of food have on the pharmacokinetic profile of T25 when administerted under high fat diet? Participants will: Take T25 under both fast and food state or mycapssa in under fast state in Day1, Day4, and Day7, 13. A follow-up visit is scheduled on D14+(7), which is 7\~14 days after the last dose of investigational product via phone/message/WeChat or in face-to-face manner.
Conditions
- Acromegaly
Interventions
T25-FastDrug
Participants received a single dose ( 8 mg, 1 tablet) on days 1, 4, and 10 unde fast state
MycapssaDrug
Participants received a single dose ( 20 mg, 1 granule on days 1, 4, and 10 under fast state
T25-FedDrug
Participants received a single dose ( 8 mg, 1 tablet) on days 1, 4, and 10 unde fed state
Primary outcomes
What the sponsor says the trial is designed to measure.
- bioavailabilityTime frame: From time 0 (administration) to 24 hours post-administration
- bioavailabilityTime frame: From time 0 (administration) to 24 hours post-administration.
- bioavailabilityTime frame: From 0 (administration) to 24hour
- bioavailabilityTime frame: From time 0 (administration) to 24 hours post-administration
- bioavailabilityTime frame: From time 0 (administration) to 24 hours post-administration.
- bioavailabilityTime frame: From time 0 (administration) to 24hour.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zibo Central Hospital
Zibo, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.